hsa‑miR‑429 targets CBX8 to promote cell apoptosis in diffuse large B‑cell lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Diffuse Large B-cell Lymphoma (DLBCL) is the most prevalent non-Hodgkin lymphoma globally.
• hsa-miR-429 is recognized for its tumor-suppressive roles in various cancers.
• The specific function of hsa-miR-429 in DLBCL remains largely uninvestigated.

Purpose of the Study:

• To elucidate the molecular mechanism of hsa-miR-429 in DLBCL.
• To determine the impact of hsa-miR-429 on DLBCL cell proliferation and apoptosis.
• To identify the direct molecular targets of hsa-miR-429 in DLBCL.

Main Methods:

• Quantitative analysis of hsa-miR-429 expression in DLBCL cell lines.
• Functional assays assessing cell proliferation and apoptosis.
• Dual luciferase reporter assays to validate gene targets.
• Gene overexpression and mimic transfection studies.

Main Results:

• hsa-miR-429 expression is significantly downregulated in DLBCL cells.
• hsa-miR-429 suppresses proliferation and induces apoptosis in DLBCL cell lines (SUDHL-4, DB).
• CBX8 is identified as a direct target of hsa-miR-429; CBX8 overexpression promotes proliferation and inhibits apoptosis.
• hsa-miR-429 counteracts the oncogenic effects of CBX8 in DLBCL cells.

Conclusions:

• hsa-miR-429 exerts tumor suppressor activity in DLBCL by targeting CBX8.
• hsa-miR-429 demonstrates potential as a diagnostic biomarker for DLBCL.
• hsa-miR-429 and its regulatory pathway involving CBX8 represent a promising therapeutic strategy for DLBCL.